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and the decrease in AF-QoL score, particularly in paroxysmal and persistent AF 
patients. CONCLUSIONS: The main impact on HRQoL in AF patients was not          
 conditioned by the type of AF, but the clinical presentation, especially number and 
frequency of symptoms.
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OBJECTIVES: To describe the experience with upper gastrointestinal (GI) symptoms, 
the impact of symptoms on daily life, and nonadherence and discontinuation of low-
dose acetylsalicylic acid (ASA) treatment in patients with cardiovascular (CV) risk. 
METHODS: Twenty-two patients from the US were selected to undergo face-to-face, 
1-hour qualitative interviews following a multicentre 3-month observational study of 
patients q18 years at risk of or with CV disease, about to begin or previously pre-
scribed daily low-dose ASA (75–325 mg) within 5 years (ClinicalTrials.gov identiﬁer: 
NCT00681759; AstraZeneca study code: D961FC00004). Interviewee-selection was 
based on low-dose ASA history, CV risk, GI medication use, and the occurrence of 
q1 upper GI event during the study period. Interviews were semi-structured and were 
audio-recorded and transcribed for analysis. RESULTS: 16 interviews were evaluable 
(mean age 44.7 years; 68.8% women); 6 patients were excluded following technical 
failure or violation of inclusion/exclusion criteria. Commonly reported upper GI 
symptoms were: burning feeling behind the breastbone (n  9); burning feeling in the 
upper stomach (n  4); acid taste in the mouth (n  4); regurgitation (n  4). Upper 
GI symptoms negatively impacted aspects of patients’ lives, including: food intake 
(n  12); sleep quality (n  6); emotions (n  5). Most patients reported occasional 
over-the-counter medication use; many altered their diet to manage upper GI symp-
toms. Overall, ﬁve patients reported treatment nonadherence. Upper GI symptoms 
caused nonadherence in 3 patients; 2 missed doses when GI symptoms were severe, 
despite being aware of low-dose ASA beneﬁts. Patients who understand the purpose 
of their low-dose ASA prescription could articulate the importance of adherence and 
the intention to continue therapy. CONCLUSIONS: Patients who understand the 
purpose of low-dose ASA treatment are more likely to adhere to therapy, although 
doses may be intentionally missed due to upper GI symptoms.
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OBJECTIVES: In patients with chronic diseases such as hypercholesterolemia, health-
related quality of life (HRQoL) is an important outcome. The objective of the present 
study was to determine factors associated with an impaired HRQoL after 12 months. 
METHODS: Patients with hypercholesterolemia were prospectively included in the 
ORBITAL (Open-label primary care study: Rosuvastatin-Based compliance Initiatives 
linked To Achievement of LDL goals) Study. Inclusion criteria were hypercholestero-
lemia with an indication for statin therapy according to the European Guidelines. 
Follow-up was 12 months. A total of 1961 primary care practices in Germany par-
ticipated. HRQoL was assessed with the Short Form (SF)-12 health status instrument. 
RESULTS: Of the 7640 patients included, 47% were high-risk patients in the primary 
prevention of coronary heart disease, 42% were patients with coronary heart disease, 
and 11% did not have a priori risk stratiﬁcation. Physical SF-12 summary scores were 
inversely associated with risk stratum, however, there was no such association between 
mental SF-12 summary scores and risk stratum. An impaired physical SF-12 score was 
associated with increased age, lower educational level, higher body mass index, 
smoking, existing coronary heart disease, a history of stroke, or a clinical event during 
follow-up. An impaired mental SF-12 score was associated with younger age, hyper-
tension, or a clinical event during follow-up. CONCLUSIONS: HRQoL in patients 
with hypercholesterolemia is associated with socioeconomic factors, lifestyle, and 
clinical events. Effective prevention is thus not only essential for clinical outcome 
but also for the maintenance of HRQoL in patients with hypercholesterolemia. 
ClinicalTrials.gov Identiﬁer: NCT00379249.
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OBJECTIVES: The assessment of quality of life among ambulatory patients with 
hypertension (HTN), diabetes type 2 (DM2) or coexisting HTN and DM2 
(HTNDM2). METHODS: Patients of 4 ambulatory care setting in Cracow (Poland) 
with HTN, DM2 or HTNDM2 were included. Polish versions of SF-36v.2 and EQ-
5D were used with the supplementary questions about age, gender, education, body 
mass, place of residence. Student’s t-test was used to compare the differences between 
paired groups. RESULTS: A total of 135 patients were included (68 with HTN, 22 
with DM2, 45 with HTNDM2); 57,8% of patients were women. 31,11% of patients 
with HTNDM2, 36,77% of patients with HTN and 72,73% of patients with DM2 
assessed their health status as well, none indicated the answer excellent or very good. 
Usually women indicated their QOL lower than men (HTN: PF, RP, PCS p  0,05; 
HTNDM2: PF, PB p  0,05). PCS was rated lower or similar to MCS; HTN: PCS 
39,30 o 7,88, MCS 40,45 o 10,96, DM2: PCS 42,77 o 8,22, MCS 42,23 o 9,86; 
HTNDM2: PCS 38,89 o 9,05, MCS 42,66 o 10,66. Due to EQ-5D 80% of patients 
had no problems with self care and 60% – with usual activities. Over 85% of patients 
had moderate or extreme pain or discomfort, more than 70% of patients felt moder-
ately or extremely anxious or depressed. About 75% of patients with HTN and 
HTNDM2 conﬁrmed problems with walking around. On VAS scale, patients with 
HTN, DM2 and HTNDM2 assessed their health state accordingly: 54,87 o 15,70, 
59,14 o 21,06, 55,56 o 14,50, with no statistically signiﬁcant differences between 
diseases and sexes. CONCLUSIONS: Patients with HTN and HTNDM2 estimated 
their quality of life lower than patients with DM2.
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OBJECTIVES: To investigate the differences in work productivity in patients with 
metabolic syndrome across three geographies. METHODS: Data from the 2008 
National Health and Wellness Survey (NHWS), an annual internet survey of attitudes, 
behaviors, health status, and outcomes of adults in the US, EU (Germany, Spain, Italy, 
UK, and France), and Japan (JPN) were used for the analysis. Metabolic syndrome 
was deﬁned as having at least three of the following: diabetes, BMI  30, high cho-
lesterol, or hypertension. Multiple regressions were used to determine the effect of 
geography on work productivity using the validated Work Productivity and Activity 
Impairment Questionnaire (WPAI) controlling for age, gender and total number of 
comorbidities. RESULTS: Of the 3,995 employed patients with metabolic syndrome 
in the analysis 881 (22.1%) were from Europe, 89 (2.2%) from JPN, and 3,025 
(75.7%) from the US. EU patients (10.9%) had signiﬁcantly higher levels of percent 
work missed in the past week due to health (absenteeism) than US (6.2%) and JPN 
(5.3%) patients. No signiﬁcant differences amongst geographies were seen for percent 
impairment at work (presenteeism), however, EU patients had higher levels of percent 
overall work impairment compared to US patients (p  0.05). For all metabolic 
patients (n  11,131) activity impairment was signiﬁcantly lower for JPN compared 
with US and EU (p  0.05). After controlling for age, gender and number of comorbid 
conditions, the differences remained signiﬁcant, with EU having higher absenteeism, 
overall work impairment, and activity impairment than the US, and JPN reporting 
less activity impairment than the US (p  0.05). CONCLUSIONS: The effect of meta-
bolic syndrome on work productivity differed signiﬁcantly across the three geogra-
phies. Any combination of factors may explain these differences: awareness of the 
condition, treatment differences, cultural issues, and health systems, amongst other. 
Further research is needed to describe the impact metabolic syndrome may have 
globally.
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OBJECTIVES: Although cardiovascular disease remains a major cause of death and 
morbidity in western countries, statins are well recognized for their role in prevention. 
The on-going need to maintain cost-effective health care has led to greater use of 
policy-driven therapeutic substitution programs for statins; however the impact of 
these policies on patients is often under-reported. METHODS: A review of published 
literature describing the impact of policy-driven statin switch programs was conducted 
based on a MEDLINE search [using the following terms: Hydroxymethylglutaryl-CoA 
Reductase Inhibitors (MeSH), and statin, switch, interchange, substitute, substitution 
(all ﬁelds); limited to English language and 1989–2009] and a review of reference lists 
from selected papers. RESULTS: Twenty-three studies were identiﬁed. Seventeen 
studies evaluated the impact of a “switch down” to equal or less potent statins. 6 
studies evaluated the impact of a “switch up” to more potent statins. Following 
introduction of “switch down” programs, 23–47% of patients were not eligible or 
willing to switch (7 studies), 17–38% of patients were switched to a non-equivalent 
(lower) dose of the new statin (3 studies), 4–11% of patients switched back to their 
original statin (5 studies), and switched patients were 19–33% less likely to be adher-
ent to therapy compared to those with no switch. Persistence was signiﬁcantly reduced 
among switch patients (2 studies). No signiﬁcant trend in lipid levels was noted (12 
studies) but loss of target levels was reported in 7–20% of patients (2 studies) and 3 
studies reported an increase in vascular events or death after switching. Studies evalu-
ating “switch up” programs consistently demonstrated improved reductions in lipid 
